Clay Siegall: Leading Cancer Research Into The Future

Seattle Genetics is quickly becoming the top name in cancer research and development of new cancer therapies to help make the word “cancer” become obsolete.

Led by CEO Clay Siegall, Seattle Genetics has been changing the way cancer is treated with the development of antibody-drug conjugates (ADCs), which specifically target cancer cells only, sparing healthy cells. Seattle Genetics has created the first ADC drug “ADCETRIS”. Mr. Siegall’s tireless work in cancer research has helped get ADCETRIS FDA approval in 2011.

Since approval, ADCETRIS has helped many cancer patients in over 60 countries have a better chance of going into a full remission with less harsh side effects as with traditional cancer treatment. This could not be accomplished without Mr. Siegall’s drive to help cancer patients be treated with cutting edge therapies that are less harsh than chemotherapy and radiation.

Mr. Siegall began his career after earning his PhD in Genetics from George Washington University. Clay started as a Research Investigator with Bristoll- Meyers Squibb and has worked his way up the scientific ladder ending with a position at the National Cancer Institute as a Biotechnology Fellow.

Mr. Siegall founded Seattle Genetics in 1998, and not only acts as the CEO of the company, Clay has raised over 1.2 billion in funding for the company’s research and development. Mr. Siegall still keeps his scientific mind sharp as he has published over 70 scientific papers and currently holds 15 scientific patents.

Mr. Siegall is very passionate about helping find ways to cure cancer and leads the scientific community in cutting edge cancer treatments.